Clinical Validation of a Targeted Next-Generation Sequencing Panel for Lymphoid Malignancies

Area of Science:

• Hematology
• Oncology
• Molecular Diagnostics

Background:

• Lymphoid malignancies are diverse hematologic disorders.
• Next-generation sequencing (NGS) offers potential for biomarker discovery.
• Challenges exist in routine NGS application for these cancers.

Purpose of the Study:

• To clinically validate a custom capture-based NGS panel.
• To detect molecular markers in lymphoproliferative and histiocytic neoplasms.
• To establish an accurate assay for lymphoid cancer characterization.

Main Methods:

• Development of a custom capture-based NGS panel.
• Clinical validation of the assay.
• Testing for single-nucleotide variants and small insertion/deletion events.

Main Results:

• The NGS panel was fully validated as a clinical assay.
• The assay demonstrated accuracy and sensitivity.
• It effectively detects key molecular alterations in lymphoid neoplasms.

Conclusions:

• The validated NGS assay is a reliable tool for characterizing lymphoid malignancies.
• This facilitates improved patient management and therapeutic strategies.
• It addresses pre-analytic and bioinformatic challenges in NGS for hematologic cancers.